• L- ornithine-L-aspartate tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-PVC or Alu-Alu blister strips to ensure the absolute chemical and physical stability of the highly hygroscopic amino acid salt.

    Active IngredientStrengthPrimary Clinical Function
    L-Ornithine L-Aspartate (LOLA)150 mg / 250 mgHepatology Maintenance Standard: Base therapeutic units for long-term chronic management of severe Non-Alcoholic Fatty Liver Disease (NAFLD), alcoholic hepatitis, and mild hyperammonemia.
    L-Ornithine L-Aspartate (LOLA)500 mgAcute Detoxification Standard: High-efficacy adult therapy utilized for immediate ammonia reduction and the step-down management of Hepatic Encephalopathy following hospital discharge.
    ExcipientsMicrocrystalline Cellulose / Crospovidone / Colloidal Silicon Dioxide / Magnesium Stearate / Premium Opadry Moisture-Barrier FilmDiluent / Superdisintegrant / Glidant / Film-Coating (Engineered specifically to lock out atmospheric moisture, preventing the heavy 500mg amino acid tablet from swelling, cracking, or prematurely degrading before it reaches the patient’s stomach)

    *Pack Sizes: 10×10 Blisters (Optimized specifically for strict, high-volume chronic hepatology dispensing regimens).

  • L-Ornithine-L-Aspartate Injection

    Free

    Product Composition & Strength

    We supply this product as a Sterile Hypertonic Solution in Glass Ampoules. (Must be diluted).

    Active IngredientStrengthConcentration
    L-Ornithine-L-Aspartate5 g (5000 mg)500 mg/ml (10 ml Ampoule)
    ExcipientsWater for Injection

    *Pack Sizes: Tray of 5 Ampoules or 10 Ampoules.

  • Rifaximin Ph.Eur Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Engineered Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute stability of the crystalline polymorph structure.

    Active IngredientStrengthPrimary Clinical Function
    Rifaximin Ph.Eur.200 mg / 400 mgGI Infection Dose: Acute eradication of non-invasive E. coli (Traveler’s Diarrhea).
    Rifaximin Ph.Eur.550 mgHepatology & IBS Standard: High-dose maintenance therapy for Hepatic Encephalopathy and IBS-D.
    ExcipientsMicrocrystalline Cellulose / Sodium Starch Glycolate / Colloidal Silicon Dioxide / Propylene GlycolDiluent / Superdisintegrant / Glidant / Film-Coating Plasticizer (Engineered for optimal dispersion throughout the intestinal lumen)

    *Pack Sizes: 10×10 Alu-Alu Blisters or 14-Tablet Blisters (Optimized specifically for standard acute infection or chronic hepatology dispensing regimens).